ArticlePediatric nephrology (Berlin, Germany)2017
Unusual severe case of hemolytic uremic syndrome due to Shiga toxin 2d-producing E. coli O80:H2.
Article in Pediatric nephrology (Berlin, Germany), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 35 citations in OpenAlex.
- Update in the diagnosis of complement-mediated thrombotic microangiopathy/atypical hemolytic uremic syndrome.Hematology. American Society of Hematology. Education Program · 2025Review
- Emerging hybrid shigatoxigenic and enteropathogenicClinical microbiology reviews · 2025Review
- Pathogenic Factors and Recent Study on the Rapid Detection of Shiga Toxin-Producing Escherichia coli (STEC).Molecular biotechnology · 2025Review
- First Isolation of the Heteropathotype Shiga Toxin-Producing and Extra-Intestinal Pathogenic (STEC-ExPEC)International journal of molecular sciences · 2024Article
- Genetic and virulence characteristics of hybrid Shiga toxin-producing and atypical enteropathogenicFrontiers in microbiology · 2024Article
- Molecular Characterization of Hetero-Pathogenic and DiarrheagenicPathogens (Basel, Switzerland) · 2023Article
- Virulence of Shigatoxigenic and EnteropathogenicVeterinary sciences · 2023Article
- Safety and Immunogenicity of a Chimeric Subunit Vaccine against Shiga Toxin-ProducingInternational journal of molecular sciences · 2023Article
- Article
- Transforming Shiga toxin-producingFrontiers in microbiology · 2023Article
- Impact of Shiga-toxin encoding gene transduction from O80:H2 Shiga toxigenic Escherichia coli (STEC) on non-STEC strains.Scientific reports · 2022Article
- Improved Molecular Diagnosis and Culture of the Emerging Heteropathotype Enterohemorrhagic Escherichia coli O80:H2 Using Its Non-Melibiose-Fermenting and Antibiotic-Resistance Properties.Journal of clinical microbiology · 2022Article
- Epidemiology and genomic analysis of Shiga toxin-producingJournal of medical microbiology · 2021Article
- Emergence of New ST301 Shiga Toxin-ProducingToxins · 2021Article
- Draft Genome Sequences of 19 ClinicalMicrobiology resource announcements · 2021Article
- Genomic Characterization of hlyF-positive Shiga Toxin-Producing Escherichia coli, Italy and the Netherlands, 2000-2019.Emerging infectious diseases · 2021Article
- Review
- Utilization of Clustered Regularly Interspaced Short Palindromic Repeats to GenotypeFrontiers in microbiology · 2020Article
- Diversity of Hybrid- and Hetero-PathogenicFrontiers in cellular and infection microbiology · 2020Review
- Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use.Pediatric nephrology (Berlin, Germany) · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHemolytic uremic syndrome (HUS) is one of the most common causes of acute renal failure in children, with the majority of cases caused by an infection with Shiga toxin-producing Escherichia coli (STEC). Whereas O157 is still the predominant STEC serotype, non-O157 serotypes are increasingly associated with STEC-HUS. However, little is known about this emerging and highly diverse group of non-O157 serotypes. With supportive therapy, STEC-HUS is often self-limiting, with occurrence of chronic sequelae in just a small proportion of patients. CASE DIAGNOSIS/TREATMENT: In this case report, we describe a 16-month-old boy with a highly severe and atypical presentation of STEC-HUS. Despite the presentation with multi-organ failure and extensive involvement of central nervous system due to extensive thrombotic microangiopathy (suggestive of atypical HUS), fecal diagnostics revealed an infection with the rare serotype: shiga toxin 2d-producing STEC O80:H2.
conclusionsThis report underlines the importance of STEC diagnostic tests in all children with HUS, including those with an atypical presentation, and emphasizes the importance of molecular and serotyping assays to estimate the virulence of an STEC strain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.